Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-08-13
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003284
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
- Conditions
- LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-08-13
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00003294
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
- Conditions
- Cervical CancerVaginal Cancer
- First Posted Date
- 2004-08-10
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 25
- Registration Number
- NCT00002562
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00003957
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 22
- Registration Number
- NCT00088829
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 74
- Registration Number
- NCT00089297
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003539
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-08-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 32
- Registration Number
- NCT00003413
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
- Conditions
- Esophageal Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00003087
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 96
- Registration Number
- NCT00003158
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.